Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel

References

• WillemzeRWHO-EORTC classification for cutaneous lymphomasBlood2005105103768378515692063
   PubMed Web of Science ®Google Scholar
• SwerdlowSHCampoEPileriSAThe 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood2016127202375239026980727
   PubMed Web of Science ®Google Scholar
• GirardiMHealdPWWilsonLDThe pathogenesis of mycosis fungoidesN Engl J Med2004350191978198815128898
   PubMed Web of Science ®Google Scholar
• OlsenEVonderheidEPimpinelliNRevisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Blood200711061713172217540844
   PubMed Web of Science ®Google Scholar
• TrautingerFEderJAssafCEuropean Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017Eur J Cancer201777577428365528
   PubMed Web of Science ®Google Scholar
• WuMChangMDPediatric Mycosis FungoidesNEJM J Watch20142014
   Google Scholar
• AgarNSWedgeworthECrichtonSSurvival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposalJ Clin Oncol201028314730473920855822
   PubMed Web of Science ®Google Scholar
• PhotiouLvan der WeydenCMccormackCMiles PrinceHSystemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary SyndromeCurr Oncol Rep20182043229572582
   PubMed Web of Science ®Google Scholar
• ZackheimHSKashani-SabetMAminSTopical corticosteroids for mycosis fungoides. Experience in 79 patientsArch Dermatol199813489499549722724
   PubMed Web of Science ®Google Scholar
• RamsayDLHalperinPSZeleniuch-JacquotteATopical mechlorethamine therapy for early stage mycosis fungoidesJ Am Acad Dermatol19881946846913183094
   PubMed Web of Science ®Google Scholar
• KimYHMartinezGVargheseAHoppeRTTopical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experienceArch Dermatol2003139216517312588222
   PubMedGoogle Scholar
• LEDAGABrief summary of the transparency committee opinion2017 https://www.has-sante.fr/portail/upload/docs/application/pdf/2018-03/ledaga_summary_ct16175.pdfAccessed June 10, 2018
   Google Scholar
• HealdPMehlmauerMMartinAGTopical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trialJ Am Acad Dermatol200349580181514576658
   PubMed Web of Science ®Google Scholar
• OlsenEAHodakEAndersonTGuidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma ConsortiumJ Am Acad Dermatol2016741275826547257
   PubMed Web of Science ®Google Scholar
• SternRSPUVA Follow-Up StudyThe risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective studyJ Am Acad Dermatol201266455356222264671
   PubMed Web of Science ®Google Scholar
• ArchierEDevauxSCastelaECarcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature reviewJ Eur Acad Dermatol Venereol201226Suppl 3223122512677
   PubMed Web of Science ®Google Scholar
• LawsPMShearNHPopeEChildhood mycosis fungoides: experience of 28 patients and response to phototherapyPediatr Dermatol201431445946424916067
   PubMed Web of Science ®Google Scholar
• SpechtLDabajaBIllidgeTWilsonLDHoppeRTInternational Lymphoma Radiation Oncology GroupModern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology GroupInt J Radiat Oncol Biol Phys2015921323925863751
   PubMed Web of Science ®Google Scholar
• QuéreuxGBrocardASaint-JeanMPhotodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: a prospective open study and review of the literatureJ Am Acad Dermatol201369689089724041738
   PubMed Web of Science ®Google Scholar
• Seyed JafariSMCazzanigaSHungerREPhotodynamic therapy as an alternative treatment for mycosis fungoides: a systemic review and meta-analysisG Ital Dermatol Venereol2018153682783229683282
   PubMed Web of Science ®Google Scholar
• JonesGWKacinskiBMWilsonLDTotal skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project GroupJ Am Acad Dermatol200247336437012196745
   PubMed Web of Science ®Google Scholar
• ElsayadKKrizJMoustakisCTotal Skin Electron Beam for Primary Cutaneous T-cell LymphomaInt J Radiat Oncol2015193510771086
   PubMed Web of Science ®Google Scholar
• European Medicines Agency - Find medicine - Targretin Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000326/human_med_001078.jsp&mid=WC0b01ac058001d124Accessed April 23, 2018
   Google Scholar
• HuenAOKimEJThe role of systemic retinoids in the treatment of cutaneous T-Cell lymphomaDermatol Clin201533471572926433844
   PubMed Web of Science ®Google Scholar
• OlsenEAInterferon in the treatment of cutaneous T-cell lymphomaDermatol Ther200316431132114686974
   PubMedGoogle Scholar
• ZackheimHSKashani-SabetMMcmillanALow-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patientsJ Am Acad Dermatol200349587387814576667
   PubMed Web of Science ®Google Scholar
• AvilesANeriNFernandez-DiezJSilvaLNamboMJInterferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphomaHematology201520953854225592781
   PubMed Web of Science ®Google Scholar
• TrautingerFPhototherapy of mycosis fungoidesG Ital Dermatol E Venereol20171526597606
   PubMed Web of Science ®Google Scholar
• WoodGSWuJMethotrexate and PralatrexateDermatol Clin201533474775526433846
   PubMed Web of Science ®Google Scholar
• QuaglinoPMauleMPrinceHMGlobal patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International ConsortiumAnn Oncol201728102517252528961843
   PubMed Web of Science ®Google Scholar
• ZackheimHSKashani-SabetMHwangSTLow-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patientsJ Am Acad Dermatol19963446266318601652
   PubMed Web of Science ®Google Scholar
• TrautingerFJustUKnoblerRPhotopheresis (extracorporeal photo-chemotherapy)Photochem Photobiol Sci2013121222822859214
   PubMed Web of Science ®Google Scholar
• VirmaniPZainJRosenSTMyskowskiPLQuerfeldCHematopoietic stem cell transplant for mycosis fungoides and sézary syndromeDermatol Clin201533480781826433851
   PubMed Web of Science ®Google Scholar
• OlsenEARookAHZicJSézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)J Am Acad Dermatol201164235240421145619
   PubMed Web of Science ®Google Scholar
• OlsenEAKimYHKuzelTMPhase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphomaJ Clin Oncol200725213109311517577020
   PubMed Web of Science ®Google Scholar
• WhittakerSJDemierreMFKimEJFinal results from a multi-center, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphomaJ Clin Oncol201028294485449120697094
   PubMed Web of Science ®Google Scholar
• European Commission Approves ADCETRIS (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy– Providing an Innovative Treatment Option to Patients Available from: https://www.takeda.com/newsroom/newsreleases/2018/european-commission-approves-adcetris-brentuximab-vedotin-for-cd30-positive-cutaneous-t-cell-lymphoma-after-one-prior-systemic-therapy-providing-an-innovative-treatment-option-to-patients/Accessed April 23, 2018
   Google Scholar
• KimYHWhittakerSHorwitzSMBrentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician’s choice (Methotrexate or Bexarotene): the phase 3 Alcanza StudyBlood201612822182182
   Web of Science ®Google Scholar
• KimYHBagotMPinter-BrownLAnti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): results from the phase III MAVORIC StudyBlood2017130Suppl 181781728576878
   PubMedGoogle Scholar
• LundinJPhase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndromeBlood2003101114267427212543862
   PubMed Web of Science ®Google Scholar
• de MassonAGuiteraPBricePLong-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomasBr J Dermatol2014170372072424438061
   PubMed Web of Science ®Google Scholar
• van SantenSRoachREvan DoornRClinical Staging and Prognostic Factors in Folliculotropic Mycosis FungoidesJAMA Dermatol20161529992100027276223
   PubMed Web of Science ®Google Scholar
• van SantenSvan DoornRNeelisKJRecommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma GroupBr J Dermatol2017177122322828132406
   PubMed Web of Science ®Google Scholar
• DemierreMFTavernaJMirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphomaJ Am Acad Dermatol200655354354416908377
   PubMed Web of Science ®Google Scholar
• VALCHLOR^™ (mechlorethamine) [package insert]Malvern, PACeptaris Therapeutics, Inc.2013
   Google Scholar
• LinerKBrownCMcgirtLClinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety dataDrug Des Devel Ther201812241254
   PubMed Web of Science ®Google Scholar
• van ScottEJKalmansonJDComplete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic toleranceCancer197332118304577503
   PubMed Web of Science ®Google Scholar
• van ScottEJWintersPLResponses of mycosis fungoides to intensive external treatment with nitrogen mustardArch Dermatol197010255075145474113
   PubMedGoogle Scholar
• HoppeRTAbelEADeneauDGPriceNMMycosis fungoides: management with topical nitrogen mustardJ Clin Oncol1987511179618033681368
   PubMed Web of Science ®Google Scholar
• PriceNMHoppeRTDeneauDGOintment-based mechlorethamine treatment for mycosis fungoidesCancer19835212221422196640491
   PubMed Web of Science ®Google Scholar
• ZachariaeHThestrup-PedersenKSøgaardHTopical nitrogen mustard in early mycosis fungoides. A 12-year experienceActa Derm Venereol198565153582578706
   PubMed Web of Science ®Google Scholar
• Beylot-BarryMDereureOVergierBPrise en charge des lymphomes T cutanés: recommandations du Groupe français d’étude des lymphomes cutanés [Management of cutaneous T-cell lymphomas: Recommendations of the French Cutaneous Lymphoma Group]Ann Dermatol Vénéréologie201013710611621 French
   PubMed Web of Science ®Google Scholar
• LessinSRDuvicMGuitartJTopical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoidesJAMA Dermatol20131491253223069814
   PubMed Web of Science ®Google Scholar
• KimYHDuvicMGuitartJTolerability and efficacy of Mechlorethamine 0.04% gel in CTCL (Mycosis Fungoides) after initial treatment with topical Mechlorethamine, 0.02% gelPresented at the T-cell Lymphoma Forum23–25 January 2014San Francisco, CA, USA Poster number TS14–1
   Google Scholar
• MathieuSRam-WolffCBaylot-BarryMD’IncanMBagotML’expérience française de l’usage du gel de chlorméthine pour le traitement du mycosis fongoïde: une série rétrospective de 107 cas du GFELC [The French experience of the use of chlormethine gel for the treatment of mycosis fungoides: a retrospective series of 107 cases of GFELC]Ann Dermatol Vénéréologie201614312S155 French
   Google Scholar
• LindahlLMFenger-GrønMIversenLSecondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort studyBr J Dermatol2014170369970424024659
   PubMed Web of Science ®Google Scholar